Search results
-
DLL3 goes trispecific
… Zelgen China ph2 data in 3rd-line SCLC presented at ASCO 2025: ORR 63% & 58% with 10mg Q2W & 30mg Q2W …
- 09/29/2025 - 12:49 -
Lyell takes on J&J and Gilead
… in r/r BCL Venue ICML 2025 EHA 2025* ASCO 2025** Setting 3rd-line-plus 2nd-line … RP2D of 2m Car-T cells. Source: company releases, EHA & ASCO 2025. Data also looked good in the second …
- 11/05/2025 - 16:50 -
NextCure joins Merck in an ovarian target
… CUSP06 OnCusp Therapeutics ADC Ph1 US data at ASCO 2025: cORR 20% (5/25) in PROC HS-20124 …
- 06/19/2025 - 11:19 -
More front-line Imdelltra details emerge
… OS Confirmatory trial following AA May 2024; data at ASCO 2025: 40% reduction in risk of death with Imdelltra vs …
- 06/12/2025 - 15:06 -
Merck speeds its KRAS into the colorectal front line
… + chemo combo) to begin Jul 2025 Ph1 Kandlelit-001 at ASCO 2025: ORR 58% (7/12) in 1st-line pts receiving triplet …
- 06/10/2025 - 10:26 -
AbbVie's telisotuzumab conjugate take two
… . This was known to enrol cMet overexpressers, but an ASCO 2025 trials-in-progress poster revealed the precise …
- 09/09/2025 - 13:04 -
ASCO 2025 movers – bispecifics to the rescue
ASCO 2025 movers – bispecifics to the rescue … presented at this year's conference. Winners of ASCO 2025 Company Share price change … use for these bispecific MAbs. Losers of ASCO 2025 Company Share price change …
- 06/30/2025 - 12:04 -
ASCO 2025 – J&J challenges its own multiple myeloma T-cell engagers
ASCO 2025 – J&J challenges its own multiple myeloma T-cell … Note: RP2D=recommended phase 2 dose. Source: ASCO 2025. This story has been updated. …
- 06/09/2025 - 10:16 -
ASCO 2025 – BioNTech shows promise in mesothelioma
ASCO 2025 – BioNTech shows promise in mesothelioma … pts) Note: *investigator-sponsored trial. Source: ASCO 2025. Still, BioNTech's data came from just 31 …
- 06/05/2025 - 17:48 -
ASCO 2025 – an early split between PD-L1 conjugates
ASCO 2025 – an early split between PD-L1 conjugates …
- 07/18/2025 - 12:16
